In a phase II study conducted by Madrigal Pharmaceuticals, it was observed that patients who were administered Resmetirom experienced notable reductions in PRO-C3 and MRI-PDFF levels[5].

This study involved patients who were initially divided into two groups: one receiving a placebo (Pbo) and the other receiving Resmetirom (Res) for a duration of 36 weeks. Subsequently, all participants continued with Resmetirom in the open-label extension (OLE) trial for an additional 36 weeks (Figure 3).

Figure 3. PRO-C3 is used as a determinant of treatment efficacy in multiple clinical trials as a secondary endpoint for antifibrotic efficacy[5]

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.